Home600664 • SHA
add
Harbin Pharmaceutical Group Co Ltd
Previous close
¥3.79
Day range
¥3.78 - ¥3.86
Year range
¥2.54 - ¥4.97
Market cap
9.55B CNY
Avg Volume
59.97M
P/E ratio
14.50
Dividend yield
-
Primary exchange
SHA
Market news
Financials
Income Statement
Revenue
Net income
(CNY) | Mar 2025info | Y/Y change |
---|---|---|
Revenue | 4.17B | 0.78% |
Operating expense | 844.30M | -9.24% |
Net income | 212.93M | 20.48% |
Net profit margin | 5.10 | 19.44% |
Earnings per share | — | — |
EBITDA | 322.56M | 3.64% |
Effective tax rate | 19.49% | — |
Balance Sheet
Total assets
Total liabilities
(CNY) | Mar 2025info | Y/Y change |
---|---|---|
Cash and short-term investments | 2.80B | -1.58% |
Total assets | 14.09B | -0.38% |
Total liabilities | 7.79B | -8.76% |
Total equity | 6.31B | — |
Shares outstanding | 2.52B | — |
Price to book | 1.71 | — |
Return on assets | 4.68% | — |
Return on capital | 8.65% | — |
Cash Flow
Net change in cash
(CNY) | Mar 2025info | Y/Y change |
---|---|---|
Net income | 212.93M | 20.48% |
Cash from operations | -464.57M | -71.56% |
Cash from investing | -17.57M | -19.17% |
Cash from financing | -271.12M | -314.72% |
Net change in cash | -753.69M | -372.72% |
Free cash flow | -538.39M | -13.57% |
About
Harbin Pharmaceutical Group Co., Ltd. is a Chinese partially state-owned company engaged in the research & development, manufacture, and sale of pharmaceutical products. HPGC medication offerings include traditional Chinese medicine and biopharmaceuticals; its main offerings include antibiotics, including amoxicillin and penicillin, and dietary supplements, including zinc gluconate and calcium gluconate.
The company owns both Renmintongtai, a drugstore chain and medical wholesaler for the domestic market, and GNC, a U.S.-based international retailer of supplements and wellness products. Wikipedia
Founded
1988
Website
Employees
10,180